23andMe's Decline Raises Serious Questions About Genomic Data Security
As 23andMe faces delisting and a plummeting valuation, experts warn that its roughly 15 million customers face unique, irreversible risks if the company fails. Advancing genomic analysis technology makes this unprotected genetic data even more dangerous than standard financial breaches.
23andMe faces a deepening crisis as its valuation drops from $6 billion to just $150 million and the company prepares for delisting next month. Following a massive data breach and the mass resignation of its independent board members, founder and CEO Anne Wojcicki's efforts to save the genetic testing company appear increasingly unreachable.
The potential collapse of 23andMe poses a unique and permanent threat to the roughly 15 million customers who entrust the company with their DNA. While a hacked credit card is easily replaceable, a compromised genome is permanent, making the potential exposure of this highly sensitive data far more consequential than traditional cyberattacks.
The underlying danger grows as the technology used to analyze genomic data advances rapidly and becomes increasingly revealing. Although 23andMe insists it remains committed to following data protection laws, experts warn that these legal safeguards offer little comfort if the company ultimately ceases to operate as a going concern.